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The immunologic challenges posed by the evolution of
viviparity were described nearly 50 years ago in the clas-
sic paper by Medawar (1953), in which he posed the
question “how does the pregnant mother contrive to
nourish within itself, for many weeks or months, a foetus
that is an antigenically foreign body?” (p. 324). At the
time this paper was written, the deleterious effects of
maternal-fetal Rh incompatibility were well known, but
antigens responsible for the rapid and violent rejection
of foreign tissues were undiscovered. It was assumed,
therefore, that maternal-fetal incompatibility for these
as-yet-undefined tissue antigens would be similarly prob-
lematic during pregnancy. Today, it is well recognized
that allograft rejection is mediated by genes of the major
histocompatibility complex (MHC), which include the
human leukocyte antigen (HLA) genes (fig. 1), and that
maternal-fetal HLA incompatibility is not deleterious
during pregnancy. However, the survival of the fetal al-
lograft in mammalian pregnancy remains a paradox.
Despite the fact that the mechanisms that induce tol-
erance during pregnancy are still not well understood,
several features of the immunologic state during preg-
nancy are clear. For example, the placenta is not an
immunologically inert barrier, as was suggested by Med-
awar (1953); rather, maternal and fetal cells are recip-
rocally transported across the placenta, and a state of
mutual tolerance exists between mother and fetus, dur-
ing normal gestation. Indeed, the transport into the ma-
ternal circulation and the long-term survival of fetal cells
(Bianchi et al. 1996) and the transport of maternal cells
into fetal tissues (Socie et al. 1994; Piotrowski and Croy
1996; Bonney and Matzinger 1997) have been well doc-
umented. The fact that immune responses against these
cells are not elicited attests to the pregnancy-induced
tolerance that is present in both mother and fetus. In
addition, fetal tolerance toward maternal cells is long
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lasting, as evidenced by the lack of responsiveness of
adult B cells to noninherited maternal HLA class I an-
tigens (Claas et al. 1988; Bean et al. 1990).
Two additional insights have come to light since Med-
awar’s (1953) classic paper, both of which have influ-
enced the context in which maternal-fetal immunology
is considered. First, the classical HLA antigens that are
responsible for the rapid rejection of allografts in hu-
mans are not present on placental cells at the maternal-
fetal interface, and, second, maternal-fetal incompati-
bility, with respect to HLA, actually may be beneficial
during pregnancy.
HLA Genes at the Maternal-Fetal Interface
The fetal cells that come into direct contact with ma-
ternal tissues in the pregnant uterus are the extravillous
cytotrophoblasts, which invade the maternal decidua.
These cells do not express any HLA class II genes (i.e.,
HLA-DR, HLA-DQ, or HLA-DP), which are strongly
immunogenic cell-surface markers in allogeneic trans-
plants. Furthermore, the class I loci HLA-A and HLA-
B, which are expressed in nearly all other nucleated cells,
are not expressed in trophoblast-cell populations. Thus,
expression of the most polymorphic and antigenic HLA
genes is suppressed in cells that are in direct contact with
the maternal immune system; instead, the nonclassical,
class I geneHLA-G is primarily expressed in these tissues
(reviewed in Le Bouteiller 1994). In addition, lower and
more transient levels of the product of the classical, class
I gene HLA-C are observed (King et al. 1996). Because
HLA-G was the first HLA gene to be described in these
tissues and because its product is the most abundant
HLA protein at the maternal-fetal interface, there has
been considerable interest in this gene.
HLA-G is an unusual HLA gene, with respect to sev-
eral features. First, although its intron-exon structure is
identical to that of the other class I genes, a premature
stop codon in exon 6 results in a shortened cytoplasmic
tail (Geraghty et al. 1987). The functional implications
(if any) of this are still unknown. Second, whereas other
class I genes are expressed in nearly all nucleated cells,
HLA-G protein has been detected only in fetal cells at
the maternal-fetal interface (reviewed in Le Bouteiller
1994). Third, HLA-G protein exists in multiple isoforms
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Figure 1 Map of human MHC on chromosome 6p21. Blackened squares represent class Ia (classical) genes, unblackened squares represent
class Ib (nonclassical) genes, and gray-shaded squares represent class I pseudogenes (HLA-H) or gene segments (HLA-J). Class II HLA genes
are shown as blackened rectangles. Complement genes are shown as gray-shaded rectangles. All other genes are shown as vertical lines. Modified
from the study by Ober and van der Ven (1996).
(fig. 2), as a result of alternative splicing (Ishitani and
Geraghty 1992; Fujii et al. 1994). These include trans-
membrane forms as well as soluble forms that lack the
transmembrane and cytoplasmic domains but that in-
clude sequences translated from “intronic” mRNA,
which are excised from the messages that encode the
membrane-spanning HLA-G isoforms. Both transmem-
brane and soluble forms include full-length isoforms
(G1) that retain the a1-domain and the a2-domain,
which form the peptide-binding domain (Ishitani and
Geraghty 1992; Fujii et al. 1994), similar to the other
HLA class I genes. Additional novel isoforms lack either
the a2-domain (G2) only or both the a2-domain and
the a3-domain (G3) (Ishitani and Geraghty 1992; Fujii
et al. 1994). The functions and timing of expression,
throughout pregnancy, of the various isoforms are not
known, but the a1-domain is capable of inhibiting nat-
ural killer (NK) cell activity (Pazmany et al. 1996;
Rouas-Freiss et al. 1997). Because NK cells are abundant
in the pregnant uterus, one important function of HLA-
G may be to protect trophoblast cells from destruction
by NK cells. However, the existence of at least five is-
oforms suggests that HLA-G may serve multiple func-
tions, including antigen presentation (Lee et al. 1995)
as well as other as-yet-unknown functions.
Last, HLA-G has very little polymorphism at both the
nucleotide and amino acid levels (reviewed in Ober and
Aldrich 1997). In contrast, the classical HLA genes are
among the most polymorphic loci in the human genome.
The limited and conservative nature of the amino acid
substitutions inHLA-Gmay permit tolerance of the fetal
allograft. Furthermore, the distribution of polymorphic
residues within the antigen-binding domain is distinct
from that seen in the classical HLA genes, suggesting
that the evolutionary constraints on HLA-G were also
different from those that influenced the distribution of
polymorphic residues at the classical loci (reviewed in
Ober and Aldrich 1997).
An exception to this conservative pattern and number
of polymorphic residues in HLA-G is found in the Af-
rican American population, in whom increased diversity
has been observed (van der Ven and Ober 1994). Re-
cently, a null mutation in HLA-G has been reported in
both African American (Ober et al., in press-a) and Span-
ish (Sua´rez et al. 1997) populations. My colleagues and
I have identified homozygotes for this mutation and have
demonstrated that the mutation is indeed a null mutation
at the protein level, eliminating expression of the pre-
dominant HLA-G1 isoforms (i.e., those that include the
a2-domain) (Ober et al., in press-a). The finding of one
multigravida woman (Ober et al., in press-a) and one
child (C. Ober, C. Aldrich, A. Reed, unpublished data)
who are homozygous for this mutation indicates that
HLA-G1 protein clearly is not necessary for fetal sur-
vival, although reduced levels of HLA-G1 protein in car-
riers of this mutation may have less obvious negative
effects on pregnancy outcome.
This null allele has been named “HLA-G*105N”
(Sua´rez et al. 1997) and occurs at frequencies of .074
in African American populations (Ober et al., in press-
a), .029 in U.S. Hispanic populations (Ober et al., in
press-a), and .061 in Spanish populations (Sua´rez et al.
1997); it was absent among 134 U.S. Caucasian chro-
mosomes (Ober et al., in press-a). The relatively high
frequency of this null allele in two distantly related pop-
ulations is curious and raises the possibility that reduced
expression of HLA-G1 protein in carriers of the HLA-
G*105N allele may be selected under certain conditions,
thereby maintaining the allele at a high frequency in
these populations. Because of the high frequency of this
allele in populations with a historically high pathogen
load, it is tempting to speculate that one function of
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Figure 2 Alternatively spliced isoforms of membrane-bound (A)
and soluble (B) HLA-G transcripts and proteins. The full-length tran-
script (HLA-G1) includes the leader peptide (L) encoded by exon 1,
the a1-domain encoded by exon 2, the a2-domain encoded by exon
3, the transmembrane domain (Tm) encoded by exon 4, the cyto-
plasmic domain (C) encoded by exons 6 and 7, and the 3′ UTR. A
premature stop codon in the second codon of exon 6 (indicated by an
asterisk [*]) results in a shortened cytoplasmic tail. In the full-length
transcript, the a1-domain and the a2-domain form the peptide-binding
domain, and the a3-domain binds to b2-microglobulin (b2m) at the
cell surface, similar to other class I molecules. Exon 3, encoding the
a2-domain, is spliced out of the G2 isoforms. Two structures have
been proposed for HLA-G2. Two G2 proteins may join at the cell
surface and form a class II–like structure (Ishitani and Geraghty 1992;
Fujii et al. 1994), or the a3-domain may bind to b2m at the cell surface
(Rouas-Freiss et al. 1997). Both exons 3 and 4 are removed from the
G3 isoform, which may be unstable at the cell surface. The two soluble
isoforms (B) include an additional 21 amino acids, following the a3-
domain, which are encoded by nucleotides from intron 4. A stop codon
(indicated by an asterisk [*]) terminates translation in intron 4, ex-
cluding amino acids encoded by exons 4–6. The additional 21 amino
acids are shown as a shaded “tail” following the a3-domain, in the
lower part of panel B. Modified from the study by Ober and Aldrich
(1997).
soluble HLA-G may be to inhibit the proliferation of
maternal T cell populations in the pregnant uterus, by
induction of cell death, as do soluble HLA-A and HLA-
B do in the periphery (Zavazava and Kronke 1996).
Maternal T cell populations are remarkably absent from
the pregnant uterus (Hunt and Soares 1996), but the
mechanisms underlying this observation are unknown.
It has been suggested that, in carriers of the HLA-
G*105N allele, the reduced expression of HLA-G1 sol-
uble protein may be associated with increased numbers
of maternal uterine T cells, which could be beneficial in
the presence of intrauterine infections (Ober and Aldrich
1997). We currently are exploring this hypothesis in pop-
ulation studies.
Maternal-Fetal HLA Compatibility
Although the classical HLA genes are not expressed
in fetal tissues at the maternal-fetal interface, maternal
antibodies against paternally derived HLA that are in-
herited by the fetus are detectable in the circulation of
∼20% of primigravidae and ∼40% of multigravidae
(Payne and Rolfs 1958; van Rood et al. 1958). Presum-
ably, sensitization is elicited by fetal nucleated cells that
enter the maternal circulation during pregnancy or at
parturition. Regardless of their origin, the presence of
anti-HLA antibodies in a significant proportion of
healthy pregnancies has demonstrated that sensitization
to paternal HLA during pregnancy is not harmful. On
the contrary, it has been suggested that these antibodies
actually may be beneficial (Beer and Billingham 1976).
The idea that maternal-fetal incompatibility, with re-
spect to MHC antigens, is advantageous in mammalian
pregnancy was first proposed in the 1960s, on the basis
of the observations that placental size was larger among
H-2–incompatible murine fetuses, compared with that
among compatible fetuses (Billington 1964; James
1965), and that implantation rates were higher for H-
2–incompatible murine zygotes, compared with those
for compatible zygotes (Kirby 1970). If human fetuses
with paternally inherited antigens that are similar to ma-
ternal antigens (i.e., histocompatible fetuses) are also at
a selective disadvantage during pregnancy, then couples
who match for HLA antigens should have poorer re-
productive outcomes, compared with couples who do
not match for HLA, because only the former can pro-
duce compatible fetuses. Indeed, the first two studies to
evaluate this hypothesis in humans demonstrated sig-
nificantly more matching at the HLA-A and HLA-B loci
among couples with a history of idiopathic recurrent
spontaneous abortion, compared with that among fertile
control couples (Komlos et al. 1977; Schacter et al.
1979). However, the 130 subsequent studies of HLA
matching in couples with recurrent miscarriage have
yielded conflicting results, and no clear relationship be-
tween HLA matching and fetal loss can be extrapolated
from these retrospective studies (reviewed in Ober and
van der Ven 1996). Nonetheless, prospective studies of
HLA matching and pregnancy outcome and studies of
maternal-fetal HLA compatibility in women with rheu-
matoid arthritis (RA) have provided support for the hy-
pothesis that HLA-incompatible fetuses are at an ad-
vantage in human pregnancy.
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HLA Matching and Fetal Loss: Prospective Studies
To elucidate the relationship between HLA matching
and pregnancy outcome, my colleagues and I have been
conducting prospective, population-based studies of the
Hutterites, for 110 years. The Hutterites provide an ex-
cellent opportunity to study the relationship between
HLA matching and pregnancy outcome, because not
only are they among the most inbred human populations
(and therefore often match for HLA), but they are also
among the most fertile (reviewed in Ober 1995). We
have not identified any Hutterite women (among 1500)
who meet the clinical definition of a recurrent aborter
(i.e., at least three spontaneous abortions and no more
than one liveborn child), but the overall miscarriage rate
is 15.6% (Ober et al., in press-b), which is similar to
that of outbred couples. Hutterite couples matching for
alleles across the entire haplotype or matching for HLA-
B antigens had significantly more fetal losses than did
couples not matching for HLA (Ober et al., in press-b).
At the present time, it is not known whether the HLA-
B locus, per se, or alleles at a locus in linkage disequi-
librium with the HLA-B alleles account for the observed
effects of HLA-B matching on fetal-loss rates among the
Hutterites. In this population, matching for alleles at
HLA-B flanking loci (HLA-C, TNFa, and C4) also was
associated with increased loss rates ( , .078, andP  .033
.043, respectively), which is consistent with an as-yet-
unknown locus that is in linkage disequilibrium with
HLA-B being the primary susceptibility locus. On the
other hand, this study considered only serologically de-
fined HLA-B antigens, which are heterogeneous at the
molecular level (So 1994). As a result, Hutterite spouses
who match for the entire haplotype will match for the
same HLA-B–locus allele, but spouses matching for ser-
ologically defined HLA-B antigens on different haplo-
types may not match for the same allele, at the molecular
level. This would result in an underestimate of the effects
of HLA-B matching on fetal loss. Regardless, these stud-
ies demonstrate that HLA matching is a significant risk
factor for sporadic fetal loss among the Hutterites.
Maternal-Fetal HLA Compatibility and Autoimmune
Disease
Despite the fact that class II antigens are not expressed
on fetal cells at the maternal-fetal interface, the pro-
duction of maternal HLA antibodies directed against
paternally derived class II genes (HLA-DR and HLA-
DQ) indicates that fetal class II antigens are recognized
by the maternal immune system. Furthermore, although
it is likely that sensitization to fetal HLA occurs most
commonly at parturition, when fetal blood spills into
the maternal circulation, there is evidence to suggest that
fetal cells expressing HLA class II antigens are recog-
nized by the mother’s system during pregnancy.
The latter hypothesis is supported by a study of 34
pregnant subjects with RA (Nelson et al. 1993). There
were significantly more maternal-fetal disparities, with
respect to alleles at the HLA-DRB1, HLA-DQB1, and
HLA-DQA1 loci, in pregnancies that were characterized
by improvement or remission of the RA, compared with
pregnancies characterized by active RA (Nelson et al.
1993). This study suggests that, during pregnancy, not
only does the maternal immune system recognize fetal
class II genes but that the maternal immune response to
these antigens differs depending on whether the fetus is
compatible or incompatible, with respect to these genes.
For example, the recognition of self antigens on fetal
cells actually may augment an autoimmune response,
whereas recognition of disparate class II antigens on fetal
cells may divert the maternal immune response away
from an autoimmune response.
The Paradox of the Fetal Allograft
The evolution of viviparity in mammalian pregnancies
presented unique challenges to the maternal immune sys-
tem during pregnancy. Immunological tolerance of an
allogeneic fetus had to be accomplished without sacrifice
to the antigenic diversity that is critical for the survival
of the species. The expression of the minimally poly-
morphic HLA-G molecule at the maternal-fetal interface
may facilitate the induction of local tolerance and may
function to inhibit NK-cell activity, perform antigen
presentation, and perhaps immunomodulate the mater-
nal T cell populations in the uterus. On the other hand,
recognition of the classical, polymorphic HLA in the
maternal periphery may elicit additional protective re-
sponses during pregnancy and may contribute to the
maintenance of genetic diversity at HLA loci.
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